| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
5,10,15,20-Tetra(pyridin-2-yl)porphyrin is a chelating agent that primarily targets metal ions. As a porphyrin derivative, it does not have specific biological receptors as its primary targets. The compound's porphyrin core allows it to coordinate with various metal ions, forming stable metalloporphyrin complexes. These complexes can interact with biological molecules and generate reactive oxygen species upon light activation. The compound's strong light-absorbing properties make it useful for photodynamic therapy and as a photosensitizer. Its primary applications are as a biochemical reagent and research tool.
|
|---|---|
| ln Vitro |
In vitro, 5,10,15,20-tetra(pyridin-2-yl)porphyrin is used as a biochemical reagent and organic compound for biomedical research. It acts as a chelating agent, primarily targeting metal ions. The compound exhibits strong light-absorbing properties and is used in various biological applications, including photodynamic therapy. Cellular assays typically evaluate its photosensitizing activity, metal chelation properties, or cytotoxicity. The compound's ability to generate reactive oxygen species upon light activation makes it valuable for studying photodynamic effects in cells.
|
| ln Vivo |
In vivo, 5,10,15,20-tetra(pyridin-2-yl)porphyrin has potential applications in photodynamic therapy (PDT) for cancer treatment. The compound's strong light-absorbing properties and ability to generate reactive oxygen species upon light activation make it a candidate for PDT. When administered to tumor-bearing animals and activated by light, the compound can induce tumor cell death through oxidative damage. Specific in vivo data is limited, but its potential as a photosensitizer is being explored. The compound is classified for research use only.
|
| Enzyme Assay |
In vitro assays for 5,10,15,20-tetra(pyridin-2-yl)porphyrin typically evaluate its photosensitizing activity or metal chelation properties. A standard protocol for photosensitization involves incubating the compound with cancer cells in growth medium at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound for a defined period, then irradiated with light at specific wavelengths (typically 400-700 nm). Cell viability is assessed using MTT or similar assays. Reactive oxygen species production is measured using fluorescent probes. For metal chelation studies, the compound is incubated with metal ions and binding is assessed using UV-Vis spectroscopy. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for 5,10,15,20-tetra(pyridin-2-yl)porphyrin typically evaluate its photodynamic activity. A standard protocol involves culturing cancer cell lines in growth medium at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound for 4-24 hours, then irradiated with light at specific wavelengths. Cell viability is assessed using MTT or similar assays. Apoptosis is evaluated using flow cytometry with Annexin V/PI staining or caspase activity assays. Reactive oxygen species production is measured using fluorescent probes. The compound's dark toxicity is assessed by treating cells without light irradiation. IC₅₀ values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for 5,10,15,20-tetra(pyridin-2-yl)porphyrin typically evaluate its photodynamic therapy efficacy in tumor-bearing mouse models. A common protocol involves subcutaneous implantation of cancer cells into immunodeficient mice. Once tumors reach appropriate size (approximately 100-200 mm³), animals are administered the compound via intravenous injection at doses determined from preliminary studies. After a suitable drug-light interval (typically 4-24 hours), tumors are irradiated with light at specific wavelengths. Tumor volume and body weight are monitored regularly. Endpoints include tumor growth inhibition, survival analysis, and histopathological examination of tumor tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 5,10,15,20-tetra(pyridin-2-yl)porphyrin is limited, as it is primarily a research reagent. The compound has a molecular weight of 618.69 g/mol and a molecular formula of C₄₀H₂₆N₈. It is a solid at room temperature and is stored at 2-8°C. As a porphyrin, it is expected to have high lipophilicity and strong protein binding. The compound's large molecular size and hydrophobic nature suggest limited oral bioavailability. Specific ADME data is not available.
|
| Toxicity/Toxicokinetics |
5,10,15,20-Tetra(pyridin-2-yl)porphyrin is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored at 2-8°C away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
5,10,15,20-Tetra(pyridin-2-yl)porphyrin (meso-Tetrakis(2-pyridyl)porphine, CAS 40904-90-3) is a biochemical reagent with the molecular formula C₄₀H₂₆N₈. It is a porphyrin derivative that acts as a chelating agent for metal ions and exhibits strong light-absorbing properties for photodynamic therapy applications. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent.
|
| Molecular Formula |
C40H26N8
|
|---|---|
| Molecular Weight |
618.69
|
| Exact Mass |
618.228
|
| CAS # |
40904-90-3
|
| PubChem CID |
135458625
|
| Appearance |
Purple to black solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.711
|
| LogP |
6.98
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
48
|
| Complexity |
887
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=NC(=C1)C2=C3C=CC(=C(C4=NC(=C(C5=CC=C(N5)C(=C6C=CC2=N6)C7=CC=CC=N7)C8=CC=CC=N8)C=C4)C9=CC=CC=N9)N3
|
| InChi Key |
SBTXZBOBSRZUPE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C40H26N8/c1-5-21-41-25(9-1)37-29-13-15-31(45-29)38(26-10-2-6-22-42-26)33-17-19-35(47-33)40(28-12-4-8-24-44-28)36-20-18-34(48-36)39(27-11-3-7-23-43-27)32-16-14-30(37)46-32/h1-24,45,48H
|
| Chemical Name |
5,10,15,20-tetrapyridin-2-yl-21,23-dihydroporphyrin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6163 mL | 8.0816 mL | 16.1632 mL | |
| 5 mM | 0.3233 mL | 1.6163 mL | 3.2326 mL | |
| 10 mM | 0.1616 mL | 0.8082 mL | 1.6163 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
